US20050060042A1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and devices for maintaining surgically created channels in a body organ
Assignee: Broncus Technologies Inc
•
Filing: 2004-07-19
•
Granted: —
•
Expires: 2024-07-19
Abstract
Abstract This is directed to methods and devices suited for maintaining an opening in a wall of a body organ for an extended period. More particularly devices and methods are directed maintaining patency of channels that alter gaseous flow within a lung to improve the expiration cycle of, for instance, an individual having chronic obstructive pulmonary disease.
Inventors
- 👤 Loc Phan
- 👤 Ed Roschak
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:45
CPC Classifications
A; A61; A61B; A61B17/00; A61B17/064; A61B17/08; A61B17/083; A61B17/10; A61B17/12; A61B17/12022; A61B17/12099; A61B17/12104; A61B17/00491; A61B17/00234; A61B2017/00238; A61B2017/00243; A61B2017/00247; A61B2017/00252; A61B2017/00743; A61B2017/00809; A61B18/00; A61B2018/00315; A61B2018/00541; A61F; A61F2/00; A61F2/02; A61F2/04; A61F2/06; A61F2002/068
Claims Analysis
Total Claims: 35
Claim 1
Independent Claim
117 words
1 . An implant for maintaining an opening in a wall of a body organ, the implant having a delivery state and an expanded state, the implant comprising a support member having a passage extending therethrough where in the delivery state a delivery diameter of the support member is less than an axial delivery length of the support member, and upon expansion the support member expands non-uniformly such that a minimum expanded diameter of the support member is greater than the delivery diameter and where a maximum expanded diameter of the support member is greater than an axial expanded length of the support member; and a composition located on the support member and comprising an antiproliferative agent.
Claim 2
Dependent Claim
117 words
1 . An implant for maintaining an opening in a wall of a body organ, the implant having a delivery state and an expanded state, the implant comprising a support member having a passage extending therethrough where in the delivery state a delivery diameter of the support member is less than an axial delivery length of the support member, and upon expansion the support member expands non-uniformly such that a minimum expanded diameter of the support member is greater than the delivery diameter and where a maximum expanded diameter of the support member is greater than an axial expanded length of the support member; and a composition located on the support member and comprising an antiproliferative agent.
Claim 3
Dependent Claim
20 words
2 . The implant of claim 1 , where the maximum expanded diameter is greater than the axial delivery length.
Claim 4
Dependent Claim
53 words
3 . The implant of claim 1 , where the support member further comprises a third portion on an end of the support member opposite to that of the second portion, the third portion is unconstrained to expand beyond the first portion, such that upon expansion the support member forms a grommet shape.
Claim 5
Dependent Claim
94 words
4 . The implant of claim 1 , where the composition comprises an amount of antiproliferative agent that does not exhibit substantial cytotoxicity but controls the healing response by suppressing hyperplasia of lung tissue, to maintain patency of an artificial opening located in the airway which allows for maintaining air passage between the opening and parenchyma for a sufficient time until the healing response of the lung tissue subsides such that the opening essentially becomes a natural airway passage. of the lung tissue subsides such that the opening essentially becomes a natural airway passage.
Claim 6
Dependent Claim
15 words
5 . The implant of claim 1 , where the composition further comprises a polymer.
Claim 7
Dependent Claim
38 words
6 . The implant of claim 5 , where the composition comprises both a release rate and an amount of antiproliferative substance sufficient to modify a healing response of the airway wall resulting from creation of the opening.
Claim 8
Dependent Claim
56 words
7 . The implant of claim 5 , where the polymer is selected from a group consisting of thermoplastic polymers , thermoset polymers, acrylate polymers, a blend of acrylate-methacrylate polymers, silicone elastomers, urethane elastomers, ethylene vinyl acetate polymers, polyethylene, polypropylene, PLA-PGA, PLA, PGA, polyortho-ester, polycapralactone, polyester, hydrogels, polystyrene, co-polymers of styrene-isobutylene-styrene, and combinations or blends thereof.
Claim 9
Dependent Claim
25 words
8 . The conduit of claim 5 , further comprising a dye located in the polymer to aid in identification of the implant during placement.
Claim 10
Dependent Claim
20 words
9 . The implant of claim 5 , where the composition fully covers an outer surface of the support member.
Claim 11
Dependent Claim
20 words
10 . The implant of claim 9 , where the polymer fully encapsulates an interior surface of the support member.
Claim 12
Dependent Claim
17 words
11 . The implant of claim 5 , where the support member comprises a second polymeric material.
Claim 13
Dependent Claim
17 words
12 . The implant of claim 11 , where the polymer and second polymeric material are bioabsorbable.
Claim 14
Dependent Claim
43 words
13 . The implant of claim 1 , where the support member has at least one pocket where the antiproliferative substance is located in the pocket, and further comprising a polymer at least covering the pocket to act as a barrier to release.
Claim 15
Dependent Claim
16 words
14 . The implant of claim 1 , where the support member comprises a metallic material.
Claim 16
Dependent Claim
25 words
15 . The implant of claim 1 , where the support member comprises a plurality of members forming a mesh having a plurality of interstices.
Claim 17
Dependent Claim
22 words
16 . The implant of claim 15 , where the composition further comprises a polymer covering the members but not the interstices.
Claim 18
Dependent Claim
17 words
17 . The implant of claim 1 , where the antiproliferative substance comprises a microtubule stabilizing agent.
Claim 19
Dependent Claim
15 words
18 . The implant of claim 17 , where the microtubule stabilizing agent is paclitaxel.
Claim 20
Dependent Claim
17 words
19 . The implant of claim 1 , where the antiproliferative substance comprises a microtubule destabilizing agent.
Claim 21
Dependent Claim
33 words
20 . The implant of claim 19 , where the microtubule destabilizing agent is selected from the group comprising vincristine, vinblastine, podophylotoxin, estramustine, noscapine, griseofulvine, dicoumarol, a vinca alkaloid, and a combination thereof.
Claim 22
Dependent Claim
30 words
21 . The implant of claim 1 , where the antiproliferative substance comprises a substance selected from the group consisting of steroids, non-steroidal anti-inflammatories, and d-actinomycin, and a combination thereof.
Claim 23
Dependent Claim
16 words
22 . The implant of claim 1 , where the antiproliferative substance comprises a cytostatic agent.
Claim 24
Dependent Claim
28 words
23 . The implant of claim 22 , where the cytostatic agent is selected from the group consisting of: sirolimus, everolimus, ABT-578, biolimus, tacrolimus, and a combination thereof.
Claim 25
Dependent Claim
14 words
24 . The implant of claim 1 , further comprising a mucus affecting substance.
Claim 26
Dependent Claim
26 words
25 . The implant of claim 25 , where the mucus affecting substance is selected from a group consisting of mucolytics, pulmozyme, and a combination thereof.
Claim 27
Dependent Claim
23 words
26 . The implant of claim 1 , further comprising at least one visualization mark disposed on a portion of the support member.
Claim 28
Dependent Claim
25 words
27 . The implant of claim 26 , where the visualization mark comprises a stripe circumferentially disposed about at least a portion the support member.
Claim 29
Dependent Claim
20 words
28 . The implant of claim 1 , further comprising a one-way valve in fluid communication with the interior passage.
Claim 30
Dependent Claim
20 words
29 . The implant of claim 1 , further comprising an antibiotic substance carried on or within the support member.
Claim 31
Dependent Claim
35 words
30 . The implant of claim 1 , the support member includes a plurality of folded control members that unfold upon expansion of the support member to limit an expanded diameter of the support member.
Claim 32
Dependent Claim
32 words
31 . The implant of claim 30 , where the folded control members form a shape selected from a group consisting of an s-shape, a v-shape, a u-shape, and a sinusoidal shape.
Claim 33
Dependent Claim
17 words
32 . The implant of claim 1 , further comprising a barrier located within the support member.
Claim 34
Dependent Claim
14 words
33 . The implant of claim 1 , further comprising a fibrin reducing substance.
Claim 35
Dependent Claim
26 words
34 . The implant of claim 33 , where the fibrin reducing substance is selected from a group consisting of streptokinase, urokinase, and tissue plasminogen activator.
References Cited (Backward Citations)
US3174851A
Cited
US3433226A
Cited
US3556079A
Cited
US3565062A
Cited
US3942530A
Cited
US4249539A
Cited
US4249541A
Cited
US4319580A
Cited
US4431006A
Cited
US4582067A
Cited
US4658817A
Cited
US4892098A
Cited
US4807634A
Cited
US5002058A
Cited
US4808153A
Cited
US4802476A
Cited
US4917097A
Cited
US5081993A
Cited
US4899757A
Cited
US5105817A
Cited
US5105816A
Cited
US5299578A
Cited
US5100423A
Cited
US5282824A
Cited
US5190528A
Cited
US5389096A
Cited
US5380316A
Cited
US5201316A
Cited
US5377682A
Cited
US6869443B2
Cited
US5704361A
Cited
US5860951A
Cited
US6032674A
Cited
US5178635A
Cited
US5295484A
Cited
US5500012A
Cited
US5383460A
Cited
US5287861A
Cited
US5275166A
Cited
US5383887A
Cited
US5402792A
Cited
US5385148A
Cited
US5484416A
Cited
US5718701A
Cited
US5855598A
Cited
US5381795A
Cited
US6344053B1
Cited
US5596989A
Cited
US6200313B1
Cited
US6013854A
Cited
US6030392A
Cited
US6013033A
Cited
US5485841A
Cited
US20020032477A1
Cited
US5873904A
Cited
US6190353B1
Cited
US5593417A
Cited
US6013093A
Cited
US5725547A
Cited
US5885219A
Cited
US5868763A
Cited
US6022371A
Cited
US6689803B2
Cited
US6010529A
Cited
US5720735A
Cited
US5876345A
Cited
US6200564B1
Cited
US6186942B1
Cited
US6036702A
Cited
US5855597A
Cited
US6024703A
Cited
US6514249B1
Cited
US6011995A
Cited
US6015405A
Cited
US6528301B1
Cited
US6336933B1
Cited
US6019789A
Cited
US6183444B1
Cited
US6174323B1
Cited
US6997189B2
Cited
US6335029B1
Cited
US6342591B1
Cited
US6533812B2
Cited
US6206831B1
Cited
US20050049615A1
Cited
US6692494B1
Cited
US20050056292A1
Cited
US20050060044A1
Cited
US6712804B2
Cited
US6872183B2
Cited
US6514290B1
Cited
US20020002401A1
Cited
US6506408B1
Cited
US20040055606A1
Cited
US6712845B2
Cited
US20050043751A1
Cited
US20050060041A1
Cited
US20050043752A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.